Nature Reviews Rheumatology - Table of Contents alert Volume 9 Issue 8

Advertisement
Current medical treatments for juvenile idiopathic arthritis (open access) Front. Pharmacol.| doi: 10.3389/fphar.2011.00060 This review by Nicolino Ruperto and Alberto Martini describes the methodological approach for performing clinical trials in JIA as well as the current available drug treatment.
TABLE OF CONTENTS
August 2013 Volume 9 Number 8
Impact Factor 5.677 *	In this issue Research Highlights News and Views Reviews Perspectives Also this month  Featured article: Post-traumatic osteoarthritis: from mouse models to clinical trials Christopher B. Little & David J. Hunter
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
New Impact Factor We are pleased to announce that the new impact factor for Nature Reviews Rheumatology is 9.745*. This places the journal first among all journals in the Rheumatology category! *2012 Journal Citation Reports® (Thomson Reuters, 2013)
RESEARCH HIGHLIGHTS Top Lupus nephritis: A rituximab-based regimen might enable oral steroid avoidance in lupus nephritis Published online: 25 June 2013 p443 | doi:10.1038/nrrheum.2013.102 PDF Spondyloarthropathies: Ligand-receptor interactions implicated in pathogenesis Published online: 16 July 2013 p444 | doi:10.1038/nrrheum.2013.116 PDF Connective tissue diseases: Immunosuppressive cells identified in mouse models of SLE Published online: 25 June 2013 p445 | doi:10.1038/nrrheum.2013.104 PDF Therapy: Ustekinumab therapeutic effects—more than skin deep Published online: 02 July 2013 p445 | doi:10.1038/nrrheum.2013.106 PDF Rheumatoid arthritis: Uncoupling bone and cartilage destruction Published online: 09 July 2013 p446 | doi:10.1038/nrrheum.2013.111 PDF Therapy: Targeting IFN-β to inflamed joints in arthritic mice Published online: 16 July 2013 p446 | doi:10.1038/nrrheum.2013.115 PDF IN BRIEF Paediatric rheumatology: HPV vaccine safe and effective in patients with JIA | Therapy: Aspirin an alternative for post-THA thromboprophylaxis | Lupus nephritis: Phase III ocrelizumab trial halted by infections | Paediatric rheumatology: Choosing between etanercept and adalimumab for JIA PDF Rheumatology JOBS of the week High-Quality Scientists Emory University More Science jobs from Rheumatology EVENT Pan Arab Rheumatology 2014 14.01.14 Dubai More science events from
NEWS AND VIEWS		Top
Paediatric rheumatology: Juvenile idiopathic arthritis—are biologic agents effective for pain? Alessandro Consolaro & Angelo Ravelli Published online: 02 July 2013 p447 | doi:10.1038/nrrheum.2013.108 Biologic medications are highly efficacious in juvenile idiopathic arthritis. However, a recent study found that a subgroup of children treated with anti-TNF agents had persistent pain despite good disease control. This finding highlights the importance of monitoring pain symptoms during treatment with modern DMARDs. Full Text | PDF
Osteoarthritis: Osteoporotic OA: a reasonable target for bone-acting agents Gabriel Herrero-Beaumont & Jorge A. Roman-Blas Published online: 16 July 2013 p448 | doi:10.1038/nrrheum.2013.113 Beneficial effects of bone-acting drugs in osteoarthritis (OA) are increasingly reported, but reliable conclusions regarding their efficacy are hindered by methodological drawbacks in study design. Identifying patients with osteoporotic OA, a phenotype defined by decreased density associated with high remodelling in subchondral bone, might improve the success of bone-directed agents. Full Text | PDF
REVIEWS		Top
Targeted therapies for systemic sclerosis Christopher P. Denton & Voon H. Ong Published online: 09 April 2013 p451 | doi:10.1038/nrrheum.2013.46 In the era of targeted therapy, patients with rheumatic diseases have seen real results. But what about those with systemic sclerosis—where is the long-awaited antifibrotic drug? Disparate aspects of the pathogenesis are gradually being integrated into a cohesive model, and molecular targets that are shared with other diseases are also being defined. As this Review stresses, careful evaluation of new strategies, with a focus on learning fundamental lessons about the underlying biology, will be needed to translate novel approaches into actual clinical progress in this recalcitrant disease. Abstract | Full Text | PDF
Causes, mechanisms and management of paediatric osteoporosis Outi Mäkitie Published online: 16 April 2013 p465 | doi:10.1038/nrrheum.2013.45 Genetic factors have critical roles in primary paediatric osteoporosis, which occurs in otherwise healthy individuals in forms that include osteogenesis imperfecta. Secondary osteoporosis results from an underlying illness and is common in children with chronic systemic inflammation, neuromuscular disabilities, or who are receiving glucocorticoid treatment. Makitie discusses the occurrence and management of paediatric osteoporosis, with a focus on prevention of skeletal complications, and highlights the need to broaden treatment options. Abstract | Full Text | PDF
Gene-function studies in systemic lupus erythematosus José C. Crispín, Christian M. Hedrich & George C. Tsokos Published online: 04 June 2013 p476 | doi:10.1038/nrrheum.2013.78 Multiple genes have been associated with susceptibility to systemic lupus erythematosus (SLE), but how do they promote disease development? In this Review, the authors examine the roles of a selected set of genes in the pathogenesis of SLE, and discuss how epigenetic modifications and microRNAs can mediate pathogenic changes in gene expression. Abstract | Full Text | PDF
Post-traumatic osteoarthritis: from mouse models to clinical trials Christopher B. Little & David J. Hunter Published online: 21 May 2013 p485 | doi:10.1038/nrrheum.2013.72 In this Review, Little and Hunter discuss the use of animal models in osteoartritis (OA) research, focusing on their importance in understanding post-traumatic OA, the human form of the disease that the models most accurately reflect. The authors also outline the approach necessary for the successful translation of scientific data into clinically useable drugs. Abstract | Full Text | PDF
PERSPECTIVES		Top
Opinion: Perspectives on imaging in axial spondyloarthritis Xenofon Baraliakos & Jürgen Braun Published online: 18 June 2013 p498 | doi:10.1038/nrrheum.2013.83 Imaging is central for the classification and diagnosis of axial spondyloarthritis, as well as for monitoring disease progression and predicting response to treatment. Xenofon Baraliakos and Jürgen Braun provide an overview of the role of imaging for patients with axial spondyloarthritis and discuss how imaging techniques might influence research and clinical practice in the future. Abstract | Full Text | PDF
Advertisement
Nature proudly sponsors the Imagine Science Film Awards Where science meets cinema Submit your film and compete for the $2,500 Nature Scientific Merit Award and the $1,000 Nature Audience Award www.imaginesciencefilms.org/festival/submit-your-film/
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2012. Nature Reviews Rheumatology was previously published as Nature Clinical Practice Rheumatology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.